Phase I study of single-agent AZD1775 (MK-1775), a wee1 kinase inhibitor, in patients with refractory solid tumors

Journal of Clinical Oncology

Volumn 33, Issue 30, 2015, Pages 3409-3415

  Do, Khanh ^a   Wilsker, Deborah ^b   Ji, Jiuping ^b   Zlott, Jennifer ^a   Freshwater, Tomoko ^c   Kinders, Robert J ^b   Collins, Jerry ^a   Chen, Alice P ^a   Doroshow, James H ^a   Kummar, Shivaani ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HISTONE H2AX; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; WEE1 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOATING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DNA DAMAGE; DRUG BLOOD LEVEL; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLATULENCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRITIS; GENE MUTATION; HEAD AND NECK CANCER; HEART PALPITATION; HOT FLUSH; HUMAN; HYPOPHOSPHATEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVARY CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QT PROLONGATION; SIDE EFFECT; SINUS TACHYCARDIA; SKIN PAIN; SOLID TUMOR; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; ENZYMOLOGY; METABOLISM; NEOPLASMS; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; YOUNG ADULT;

EID: 84945181744     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.4009     Document Type: Article

References (21)

1. Wantanabe N, Broome M, Hunter T: Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J 14:1878-1891, 1995
2. Domínguez-Kelly R, Martín Y, Koundrioukoff S, et al: Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol 194:567-579, 2011
3. Beck H, Nähse-Kumpf V, Larsen MS, et al: Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol 32:4226-4236, 2012
4. Hirai H, Arai T, Okada M, et al: MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 9:514-522, 2010
5. Hirai H, Iwasawa Y, Okada M, et al: Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 8:2992-3000, 2009
6. Rajeshkumar NV, De Oliveira E, Ottenhof N, et al: MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 17:2799-2806, 2011
7. Guertin AD, Li J, Liu Y, et al: Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol CancerTher 12:1442-1452, 2013
8. Kreahling JM, Gemmer JY, Reed D, et al. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 11:174-182, 2012
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
10. Kinders RJ, Hollingshead M, Lawrence S, et al: Development of a validated immunofluorescence assay for yH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin Cancer Res 16:5447-5457, 2010
11. Yu X, Chini CC, He M, et al: The BRCT domain is a phospho-protein binding domain. Science 302 639-642, 2003
12. Clark SL, Rodriguez AM, Snyder RR, et al. Structure-function of the tumor suppressor BRCA1. Comput Struct Biotechnol J 1(1), 2012
13. Lin SY, Li K, Stewart GS, et al: Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation. Proc Natl Acad Sci U S A 101:6484-6489, 2004
14. Bridges KA, Hirai H, Buser CA, et al: MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 17: 5638-5648, 2011
15. Leijen S, Beijnen JH, Schellens JH: Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 5:186-191, 2010
16. Fikaris AJ, Lewis AE, Abulaiti A, et al: Ras triggers ataxia-telangiectasia-mutated and Rad-3-related activation and apoptosis through sustained mitogenic signaling. J Biol Chem 281:34759-34767, 2006
17. Russell MR, Levin K, Rader J, et al: Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res 73:776-784, 2013
18. Chilà R, Basana A, Lupi M, et al: Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Oncotarget 6:3394-3408, 2015
19. Weisberg E, Nonami A, Chen Z, et al: Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia 29:27-37, 2015
20. Gwinn DM, Asara JM, Shaw RJ: Raptor is phosphorylated by cdc2 during mitosis. PLoS One 5:e9197, 2010
21. Min W, Bruhn C, Grigaravicius P, et al: Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation. Nat Commun 4:2993 2013